Format

Send to

Choose Destination
Vaccine. 2010 Jul 12;28(31):5109-13. doi: 10.1016/j.vaccine.2010.03.080. Epub 2010 May 12.

The effect of anti-TNF treatment on the immunogenicity and safety of the 7-valent conjugate pneumococcal vaccine in children with juvenile idiopathic arthritis.

Author information

1
1st Department of Pediatrics, Pediatric Immunology and Rheumatology Referral Center, Hippokration General Hospital, Aristotle University of Thessaloniki, 49 Konstantinoupoleos St., 54642 Thessaloniki, Greece. farmakg@med.auth.gr

Abstract

Our aim was to study the effect of anti-TNF treatment on immunogenicity and safety of the 7-valent conjugate pneumococcal vaccine in children with juvenile idiopathic arthritis. Thirty-one children (mean age:12.9+/-4.6 years) treated with anti-TNFs plus Disease Modifying Anti-Rheumatic Drugs (DMARDs) and 32 age-matched children treated only with DMARDs were vaccinated with two doses of PCV7. After the first vaccine dose geometric mean titers (GMTs) were significantly increased for all vaccine serotypes (p<0.0001) in both groups and were found to be protective (>0.35microg/ml) in 87-100% of all children, depending on the serotype. Children receiving anti-TNFs achieved a significantly lower GMTs against serotypes 4, 14 and 23F (p<0.05). A >or=4-fold increase of the baseline titers to >or=5 vaccine serotypes was observed in 50% and 75% of the anti-TNF and control patients, respectively (p=0.0697). No patient developed vaccine-associated serious adverse events or disease flares.

PMID:
20470802
DOI:
10.1016/j.vaccine.2010.03.080
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center